Sfoglia per Autore
EAU Guidelines on Penile Cancer: 2014 Update
2015-01-01 Hakenberg, Ow; Comperat, Em; Minhas, S; Necchi, A; Protzel, C; Watkin, N
Clinical Outcome in Testicular Sex Cord Stromal Tumors: Testis Sparing vs Radical Orchiectomy and Management of Advanced Disease
2015-01-01 Nicolai, N; Necchi, A; Raggi, D; Biasoni, D; Catanzaro, M; Piva, L; Stagni, S; Maffezzini, M; Torelli, T; Fare, E; Giannatempo, P; Pizzocaro, G; Colecchia, M; Salvioni, R
Clinical Outcomes of Metastatic Poor Prognosis Germ Cell Tumors: Current Perspective From a Referral Center
2015-01-01 Necchi, A; Fare, E; Lo Vullo, S; Giannatempo, P; Raggi, D; Nicolai, N; Piva, L; Biasoni, D; Catanzaro, M; Torelli, T; Stagni, S; Maffezzini, M; Verzoni, E; Grassi, P; Procopio, G; Pizzocaro, G; Mariani, L; Salvioni, R
Impact of the Number of Prior Lines of Therapy and Prior Perioperative Chemotherapy in Patients Receiving Salvage Therapy for Advanced Urothelial Carcinoma: Implications for Trial Design
2015-01-01 Pond, Gr; Bellmunt, J; Rosenberg, Je; Bajorin, Df; Regazzi, Am; Choueiri, Tk; Qu, Aq; Niegisch, G; Albers, P; Necchi, A; Di Lorenzo, G; Fougeray, R; Wong, Yn; Sridhar, Ss; Ko, Yj; Milowsky, Mi; Galsky, Md; Sonpavde, G
High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment of patients with poor prognosis germ-cell tumors: mature results of an Italian randomized phase II study
2015-01-01 Necchi, A; Mariani, L; Di Nicola, M; Lo Vullo, S; Nicolai, N; Giannatempo, P; Raggi, D; Fare, E; Magni, M; Piva, L; Matteucci, P; Catanzaro, M; Biasoni, D; Torelli, T; Stagni, S; Bengala, C; Barone, C; Schiavetto, I; Siena, S; Carlo-Stella, C; Pizzocaro, G; Salvioni, R; Gianni, Am
Cisplatin-Based First-Line Therapy for Advanced Urothelial Carcinoma After Previous Perioperative Cisplatin-Based Therapy
2015-01-01 Necchi, A; Pond, Gr; Giannatempo, P; Di Lorenzo, G; Eigl, Bj; Locke, J; Pal, Sk; Agarwal, N; Poole, A; Vaishampayan, Un; Niegisch, G; Hussain, Sa; Singh, P; Bellmunt, J; Sonpavde, G
Relationship between lymph node ratio and cancer-specific survival in a contemporary series of patients with penile cancer and lymph node metastases
2015-01-01 Lughezzani, G; Catanzaro, M; Torelli, T; Piva, L; Biasoni, D; Stagni, S; Necchi, A; Giannatempo, P; Raggi, D; Fare, E; Colecchia, M; Pizzocaro, G; Salvioni, R; Nicolai, N
Complete Response as an Intermediate End Point in Patients Receiving Salvage Systemic Therapy for Urothelial Carcinoma sdfhzdfh
2015-01-01 Sonpavde, G; Pond, Gr; Rosenberg, Je; Bajorin, Df; Regazzi, Am; Choueiri, Tk; Qu, Aq; Niegisch, G; Albers, P; Necchi, A; Di Lorenzo, G; Fougeray, R; Dreicer, R; Chen, Yh; Wong, Yn; Sridhar, Ss; Ko, Yj; Milowsky, Mi; Galsky, Md; Bellmunt, J
A Prognostic Model Including Pre- and Postsurgical Variables to Enhance Risk Stratification of Primary Mediastinal Nonseminomatous Germ Cell Tumors: The 27-Year Experience of a Referral Center
2015-01-01 Necchi, A; Giannatempo, P; Lo Vullo, S; Fare, E; Raggi, D; Marongiu, M; Scanagatta, P; Duranti, L; Giovannetti, R; Girelli, L; Nicolai, N; Piva, L; Biasoni, D; Torelli, T; Catanzaro, M; Stagni, S; Maffezzini, M; Gianni, Am; Mariani, L; Pastorino, U; Salvioni, R
Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer
2015-01-01 Galsky, Md; Pal, Sk; Chowdhury, S; Harshman, Lc; Crabb, Sj; Wong, Yn; Yu, Ey; Powles, T; Moshier, El; Ladoire, S; Hussain, Sa; Agarwal, N; Vaishampayan, Un; Recine, F; Berthold, D; Necchi, A; Theodore, C; Milowsky, Mi; Bellmunt, J; Rosenberg, Je
TOKIO rationale and protocol: a phase II study to evaluate the activity and safety of third -line tyrosine kinase inhibitor after 2 tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma
2015-01-01 Verzoni, E; Grassi, P; Montone, R; Galli, G; Necchi, A; Procopio, G
Immunohistochemistry to Enhance Prognostic Allocation and Guide Decision-Making of Patients With Advanced Urothelial Cancer Receiving First-Line Chemotherapy
2015-01-01 Necchi, A; Giannatempo, P; Paolini, B; Lo Vullo, S; Marongiu, M; Fare, E; Raggi, D; Nicolai, N; Piva, L; Catanzaro, M; Biasoni, D; Torelli, T; Stagni, S; Maffezzini, M; Gianni, Am; De Braud, F; Mariani, L; Sonpavde, G; Colecchia, M; Salvioni, R
Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma: a systematic review and meta-analysis of patient outcomes
2015-01-01 Giannatempo, P; Greco, T; Mariani, L; Nicolai, N; Tana, S; Farè, E; Raggi, D; Piva, L; Catanzaro, M; Biasoni, D; Torelli, T; Stagni, S; Avuzzi, B; Maffezzini, M; Landoni, Giovanni; De Braud, F; Gianni, Am; Sonpavde, G; Salvioni, R; Necchi, A.
Incomplete Cross-Resistance Between Taxanes for Advanced Urothelial Carcinoma: Implications for Clinical Practice and Trial Design
2015-01-01 Sonpavde, G; Pond, Gr; Mullane, S; Qu, Aq; Di Lorenzo, G; Federico, P; Necchi, A; Rosenberg, Je; Bellmunt, J; Choueiri, Tk
Prognostic reclassification of patients with intermediate-risk metastatic germ cell tumors : implications for clinical practice, trial design, and molecular interrogation
2015-01-01 Raggi, D.; Mariani, L.; Giannatempo, P.; Lo Vullo, S.; Giardiello, D.; Nicolai, N.; Piva, L.; Biasoni, D.; Catanzaro, M.; Torelli, T.; Stagni, S.; Maffezzini, M.; Calareso, G.; Magni, M.; Di Nicola, M.; Verzoni, E.; Grassi, P.; Procopio, G.; De Braud, F.; Pizzocaro, G.; Salvioni, R.; Necchi, A.
Postchemotherapy Lymphadenectomy in Patients With Metastatic Urothelial Carcinoma: Long-Term Efficacy and Implications for Trial Design
2015-01-01 Necchi, A; Giannatempo, P; Lo Vullo, S; Fare, E; Raggi, D; Nicolai, N; Piva, L; Biasoni, D; Torelli, T; Catanzaro, M; Stagni, S; Maffezzini, M; Mariani, L; Salvioni, R
Bladder Cancer Patient Advocacy: A Global Perspective
2015-01-01 Quale, Dz; Bangs, R; Smith, M; Guttman, D; Northam, T; Winterbottom, A; Necchi, A; Fiorini, E; Demkiw, S
Clinical experience with temsirolimus in the treatment of advanced renal cell carcinoma
2015-01-01 Zanardi, E.; Verzoni, E.; Grassi, P.; Necchi, A; Giannatempo, P.; Raggi, D.; de Braud, F.; Procopio, G.
Nausea and vomiting during the first 3 intercycle periods in chemo-naive cancer patients receiving moderately/highly emetogenic therapy
2015-01-01 Pessi, Ma; Necchi, A; Bossi, P; Resteghini, C; Giannatempo, P; Ferrari, L; Zilembo, N; Ripamonti, Ci
High-dose chemotherapy for germ cell tumors: do we have a model?
2015-01-01 Necchi, A; Lanza, F; Rosti, G; Martino, M; Fare, E; Pedrazzoli, P
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| EAU Guidelines on Penile Cancer: 2014 Update | 1-gen-2015 | Hakenberg, Ow; Comperat, Em; Minhas, S; Necchi, A; Protzel, C; Watkin, N | |
| Clinical Outcome in Testicular Sex Cord Stromal Tumors: Testis Sparing vs Radical Orchiectomy and Management of Advanced Disease | 1-gen-2015 | Nicolai, N; Necchi, A; Raggi, D; Biasoni, D; Catanzaro, M; Piva, L; Stagni, S; Maffezzini, M; Torelli, T; Fare, E; Giannatempo, P; Pizzocaro, G; Colecchia, M; Salvioni, R | |
| Clinical Outcomes of Metastatic Poor Prognosis Germ Cell Tumors: Current Perspective From a Referral Center | 1-gen-2015 | Necchi, A; Fare, E; Lo Vullo, S; Giannatempo, P; Raggi, D; Nicolai, N; Piva, L; Biasoni, D; Catanzaro, M; Torelli, T; Stagni, S; Maffezzini, M; Verzoni, E; Grassi, P; Procopio, G; Pizzocaro, G; Mariani, L; Salvioni, R | |
| Impact of the Number of Prior Lines of Therapy and Prior Perioperative Chemotherapy in Patients Receiving Salvage Therapy for Advanced Urothelial Carcinoma: Implications for Trial Design | 1-gen-2015 | Pond, Gr; Bellmunt, J; Rosenberg, Je; Bajorin, Df; Regazzi, Am; Choueiri, Tk; Qu, Aq; Niegisch, G; Albers, P; Necchi, A; Di Lorenzo, G; Fougeray, R; Wong, Yn; Sridhar, Ss; Ko, Yj; Milowsky, Mi; Galsky, Md; Sonpavde, G | |
| High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment of patients with poor prognosis germ-cell tumors: mature results of an Italian randomized phase II study | 1-gen-2015 | Necchi, A; Mariani, L; Di Nicola, M; Lo Vullo, S; Nicolai, N; Giannatempo, P; Raggi, D; Fare, E; Magni, M; Piva, L; Matteucci, P; Catanzaro, M; Biasoni, D; Torelli, T; Stagni, S; Bengala, C; Barone, C; Schiavetto, I; Siena, S; Carlo-Stella, C; Pizzocaro, G; Salvioni, R; Gianni, Am | |
| Cisplatin-Based First-Line Therapy for Advanced Urothelial Carcinoma After Previous Perioperative Cisplatin-Based Therapy | 1-gen-2015 | Necchi, A; Pond, Gr; Giannatempo, P; Di Lorenzo, G; Eigl, Bj; Locke, J; Pal, Sk; Agarwal, N; Poole, A; Vaishampayan, Un; Niegisch, G; Hussain, Sa; Singh, P; Bellmunt, J; Sonpavde, G | |
| Relationship between lymph node ratio and cancer-specific survival in a contemporary series of patients with penile cancer and lymph node metastases | 1-gen-2015 | Lughezzani, G; Catanzaro, M; Torelli, T; Piva, L; Biasoni, D; Stagni, S; Necchi, A; Giannatempo, P; Raggi, D; Fare, E; Colecchia, M; Pizzocaro, G; Salvioni, R; Nicolai, N | |
| Complete Response as an Intermediate End Point in Patients Receiving Salvage Systemic Therapy for Urothelial Carcinoma sdfhzdfh | 1-gen-2015 | Sonpavde, G; Pond, Gr; Rosenberg, Je; Bajorin, Df; Regazzi, Am; Choueiri, Tk; Qu, Aq; Niegisch, G; Albers, P; Necchi, A; Di Lorenzo, G; Fougeray, R; Dreicer, R; Chen, Yh; Wong, Yn; Sridhar, Ss; Ko, Yj; Milowsky, Mi; Galsky, Md; Bellmunt, J | |
| A Prognostic Model Including Pre- and Postsurgical Variables to Enhance Risk Stratification of Primary Mediastinal Nonseminomatous Germ Cell Tumors: The 27-Year Experience of a Referral Center | 1-gen-2015 | Necchi, A; Giannatempo, P; Lo Vullo, S; Fare, E; Raggi, D; Marongiu, M; Scanagatta, P; Duranti, L; Giovannetti, R; Girelli, L; Nicolai, N; Piva, L; Biasoni, D; Torelli, T; Catanzaro, M; Stagni, S; Maffezzini, M; Gianni, Am; Mariani, L; Pastorino, U; Salvioni, R | |
| Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer | 1-gen-2015 | Galsky, Md; Pal, Sk; Chowdhury, S; Harshman, Lc; Crabb, Sj; Wong, Yn; Yu, Ey; Powles, T; Moshier, El; Ladoire, S; Hussain, Sa; Agarwal, N; Vaishampayan, Un; Recine, F; Berthold, D; Necchi, A; Theodore, C; Milowsky, Mi; Bellmunt, J; Rosenberg, Je | |
| TOKIO rationale and protocol: a phase II study to evaluate the activity and safety of third -line tyrosine kinase inhibitor after 2 tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma | 1-gen-2015 | Verzoni, E; Grassi, P; Montone, R; Galli, G; Necchi, A; Procopio, G | |
| Immunohistochemistry to Enhance Prognostic Allocation and Guide Decision-Making of Patients With Advanced Urothelial Cancer Receiving First-Line Chemotherapy | 1-gen-2015 | Necchi, A; Giannatempo, P; Paolini, B; Lo Vullo, S; Marongiu, M; Fare, E; Raggi, D; Nicolai, N; Piva, L; Catanzaro, M; Biasoni, D; Torelli, T; Stagni, S; Maffezzini, M; Gianni, Am; De Braud, F; Mariani, L; Sonpavde, G; Colecchia, M; Salvioni, R | |
| Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma: a systematic review and meta-analysis of patient outcomes | 1-gen-2015 | Giannatempo, P; Greco, T; Mariani, L; Nicolai, N; Tana, S; Farè, E; Raggi, D; Piva, L; Catanzaro, M; Biasoni, D; Torelli, T; Stagni, S; Avuzzi, B; Maffezzini, M; Landoni, Giovanni; De Braud, F; Gianni, Am; Sonpavde, G; Salvioni, R; Necchi, A. | |
| Incomplete Cross-Resistance Between Taxanes for Advanced Urothelial Carcinoma: Implications for Clinical Practice and Trial Design | 1-gen-2015 | Sonpavde, G; Pond, Gr; Mullane, S; Qu, Aq; Di Lorenzo, G; Federico, P; Necchi, A; Rosenberg, Je; Bellmunt, J; Choueiri, Tk | |
| Prognostic reclassification of patients with intermediate-risk metastatic germ cell tumors : implications for clinical practice, trial design, and molecular interrogation | 1-gen-2015 | Raggi, D.; Mariani, L.; Giannatempo, P.; Lo Vullo, S.; Giardiello, D.; Nicolai, N.; Piva, L.; Biasoni, D.; Catanzaro, M.; Torelli, T.; Stagni, S.; Maffezzini, M.; Calareso, G.; Magni, M.; Di Nicola, M.; Verzoni, E.; Grassi, P.; Procopio, G.; De Braud, F.; Pizzocaro, G.; Salvioni, R.; Necchi, A. | |
| Postchemotherapy Lymphadenectomy in Patients With Metastatic Urothelial Carcinoma: Long-Term Efficacy and Implications for Trial Design | 1-gen-2015 | Necchi, A; Giannatempo, P; Lo Vullo, S; Fare, E; Raggi, D; Nicolai, N; Piva, L; Biasoni, D; Torelli, T; Catanzaro, M; Stagni, S; Maffezzini, M; Mariani, L; Salvioni, R | |
| Bladder Cancer Patient Advocacy: A Global Perspective | 1-gen-2015 | Quale, Dz; Bangs, R; Smith, M; Guttman, D; Northam, T; Winterbottom, A; Necchi, A; Fiorini, E; Demkiw, S | |
| Clinical experience with temsirolimus in the treatment of advanced renal cell carcinoma | 1-gen-2015 | Zanardi, E.; Verzoni, E.; Grassi, P.; Necchi, A; Giannatempo, P.; Raggi, D.; de Braud, F.; Procopio, G. | |
| Nausea and vomiting during the first 3 intercycle periods in chemo-naive cancer patients receiving moderately/highly emetogenic therapy | 1-gen-2015 | Pessi, Ma; Necchi, A; Bossi, P; Resteghini, C; Giannatempo, P; Ferrari, L; Zilembo, N; Ripamonti, Ci | |
| High-dose chemotherapy for germ cell tumors: do we have a model? | 1-gen-2015 | Necchi, A; Lanza, F; Rosti, G; Martino, M; Fare, E; Pedrazzoli, P |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile